Citation & Authors
Diabetes Obes Metab. 2025;27(12):7299-7308.
ABSTRACT · RESEARCH SUMMARY
Research summary
In a target trial emulation involving patients aged ≥60 years with type 2 diabetes, SGLT2 inhibitors were associated with lower risks of nonexudative macular degeneration (HR 0.64; 95% CI 0.49–0.84) and exudative degeneration than DPP-4 inhibitors, but with a slightly increased risk of cataract (1.08; 1.02–1.15). Atrophic degeneration, ocular hypertension, and glaucoma did not differ significantly.
Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗
